Document Detail


Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjögren's syndrome.
MedLine Citation:
PMID:  22692396     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Antiphospholipid antibodies (aPL) and antiphospholipid syndrome (APS) have been described in primary Sjögren's syndrome (pSS) with controversial findings regarding aPL prevalence and their association with thrombotic events. We evaluated 100 consecutive pSS patients (American-European criteria) and 89 age-gender-ethnicity-matched healthy controls for IgG/IgM anticardiolipin (aCL), IgG/IgM anti-beta2-glycoprotein-I (aβ2GPI), and lupus anticoagulant (LA) (positivity according to APS Sydney's criteria). Clinical analysis followed standardized interview and physical examination assessing thrombotic and nonthrombotic APS manifestations and thrombosis risk factors. aPLs were detected in 16 % patients and 5.6 % controls (p = 0.035). LA was the most common aPL in patients (9 %), followed by aβ2GPI (5 %) and aCL (4 %). Thrombotic events occurred in five patients [stroke in two, myocardial infarction in one and deep-vein thrombosis (DVT) in four], but in none of controls (p = 0.061). Mean age at time of stroke was 35 years. Three patients with thrombotic events (including the two with stroke) had APS (Sydney's criteria) and were positive exclusively for LA. Comparison of patients with (n = 16) and without (n = 84) aPL revealed similar mean age, female predominance, and ethnicity (p > =0.387). Frequencies of livedo reticularis (25 vs. 4.8 %, p = 0.021), stroke (12.5 vs. 0 %, p = 0.024), and DVT (18.8 vs. 1.2 %, p = 0.013) were significantly higher in APL + patients. Conversely, frequencies of hypertension, dyslipidemia, diabetes, obesity, smoking, sedentarism, and hormonal contraception were similar in patients with or without aPL (p ≥ 0.253). Our study identified LA as an important marker for APS in pSS, particularly for stroke in young patients, warranting routine evaluation of these antibodies and rigorous intervention in modifiable risk factors.
Authors:
Sandra Gofinet Pasoto; Henrique Pires Chakkour; Renato Romera Natalino; Vilma S T Viana; Cleonice Bueno; Alessandro Cavalcanti Lianza; José Lázaro de Andrade; Mauricio Levy Neto; Ricardo Fuller; Eloisa Bonfa
Related Documents :
21682756 - Anti-viral therapy in haemodialysed hcv patients: efficacy, tolerance and treatment str...
22703866 - Vascular calcification in rheumatoid arthritis: prevalence, pathophysiological aspects ...
16500696 - Sialic acid is an inflammation marker associated with a history of deep vein thrombosis.
8493456 - Lipid abnormalities in chronic uremic patients. response to treatment with gemfibrozil.
16700846 - Frequency of hoover's sign in stable patients with chronic obstructive pulmonary disease.
7442976 - Traumatic cerebral mass lesions: correlations between clinical, intracranial pressure, ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-6-13
Journal Detail:
Title:  Clinical rheumatology     Volume:  -     ISSN:  1434-9949     ISO Abbreviation:  -     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-6-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8211469     Medline TA:  Clin Rheumatol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina, Universidade de São Paulo (USP), São Paulo, Brazil, sandrapasoto@yahoo.com.br.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Photo-impulsive reactions in the electronic ground state without electronic excitation: non-photo, n...
Next Document:  Vitamin D and polymorphisms of VDR gene in patients with systemic lupus erythematosus.